Martine Zimmermann
Director/Board Member chez INVENTIVA
Fortune : 167 034 $ au 31/03/2024
Profil
Martine Zimmermann is an Independent Director at Ligand Pharmaceuticals, Inc. and Inventiva SA. She is also the SVP and Head of Regulatory Affairs and R&D Quality at Ipsen Biopharmaceuticals, Inc. Previously, she worked as a Director at Caelum Biosciences, Inc. and as the Senior VP and Head of Global Regulatory Affairs at Alexion Pharmaceuticals, Inc. She holds a doctorate degree from both the University of Strasbourg and Louis Pasteur University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 22/09/2023 | 2 285 ( 0,01% ) | 167 034 $ | 31/03/2024 |
Postes actifs de Martine Zimmermann
| Sociétés | Poste | Début |
|---|---|---|
| INVENTIVA | Director/Board Member | 16/04/2021 |
| LIGAND PHARMACEUTICALS INCORPORATED | Director/Board Member | 26/09/2023 |
| Ipsen Biopharmaceuticals, Inc. | General Counsel | - |
Anciens postes connus de Martine Zimmermann
| Sociétés | Poste | Fin |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | General Counsel | 01/02/2023 |
Caelum Biosciences, Inc.
 Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Director/Board Member | 01/01/2021 |
Formation de Martine Zimmermann
| University of Strasbourg | Doctorate Degree |
| Louis Pasteur University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
| INVENTIVA | Health Technology |
| Entreprise privées | 3 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
| Ipsen Biopharmaceuticals, Inc. | |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Health Technology |
